Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer

Oct 12, 2010

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy patients with good prognostic factors.

Those whose cancers relapse or do not respond to upfront therapy currently have few second-line treatment options and palliative care is the option in the majority of cases.

Dr Andrea Necchi from Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and colleagues have begun a Phase-II trial using pazopanib in this setting. Pazopanib is a selective inhibitor of several signaling pathways that contribute to and the development of new cancer-related blood vessels (angiogenesis).

So far, the researchers have enrolled 18 patients of a total of 41 planned. Each participant had metastatic urothelial cancer that had already failed to respond to at least one prior chemotherapy regimen. This means that investigators treated many patients who had already failed more than two chemotherapy regimens. Patients were administered 800mg of the drug once daily until their disease progressed or they experienced unacceptable toxicity.

"Thus far, four patients have seen their tumors shrink but, much more interestingly, the great majority of the patients --twelve out of eighteen-- saw their metastases begin to die," Dr Necchi said.

The death of these metastatic tumors, described formally as 'necrotic evolution', was observed by the researchers on monthly computed tomography and positron scans.

"Considering this drug partly acts to prevent tumors recruiting the blood supplies they need to live and grow, necrotic evolution of is not completely surprising," Dr Necchi said. "But this is the first time we have seen this phenomenon in so many cases of urothelial cancer. The challenge is to translate this kind of activity into a survival advantage."

"Of course we are only at the first step of this Phase-II trial and caution is needed when interpreting results," Dr Necchi said. "A longer follow-up time and greater sample size are needed before we can declare the study a success. However, for the first time in this disease we are generating interest among investigators and, particularly, of pharmaceutical industry."

The current trial is independent of the pharmaceutical industry, Dr Necchi noted. The sponsor is Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. "The study shows that it is possible in Europe to promote independent research that focuses attention on challenging problematic matters, such as salvage therapy in urothelial cancer."

"These preliminary results underline the value of angiogenesis as a target in bladder cancer," commented Dr Joaquim Bellmunt, Section Chief, Solid Tumor Oncology at Hospital del Mar in Barcelona, Spain. "They add to results other groups have published recently using similar drugs to treat bladder cancer."

Explore further: Six percent of colorectal cancer found to be interval tumors

Provided by European Society for Medical Oncology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Investigational drug shows promise in ovarian cancer

Sep 15, 2008

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical ...

Melanoma drug shrinks brain metastases in phase I/II study

Oct 12, 2010

A new drug being developed to treat potentially deadly melanoma skin cancers has shown a promising ability to shrink secondary tumors, known as metastases, in the brain in patients with advanced forms of the disease, Australian ...

Recommended for you

Physicians target the genes of lung, colon cancers

9 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Researchers see hospitalization records as additional tool

Comparing hospitalization records with data reported to local boards of health presents a more accurate way to monitor how well communities track disease outbreaks, according to a paper published April 16 in the journal PLOS ON ...

Ebola virus in Africa outbreak is a new strain

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.